TY - JOUR
T1 - Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models
AU - Menalled, Liliana
AU - El-Khodor, Bassem F.
AU - Patry, Monica
AU - Suárez-Fariñas, Mayte
AU - Orenstein, Samantha J.
AU - Zahasky, Benjamin
AU - Leahy, Christina
AU - Wheeler, Vanessa
AU - Yang, X. William
AU - MacDonald, Marcy
AU - Morton, A. Jennifer
AU - Bates, Gill
AU - Leeds, Janet
AU - Park, Larry
AU - Howland, David
AU - Signer, Ethan
AU - Tobin, Allan
AU - Brunner, Daniela
N1 - Funding Information:
We are grateful to Drs. Michael Hayden and Blair Leavitt for YAC128 mice, Dr. Jeff Schneider for the statistical support, Dr. Marie Françoise Chesselet, for numerous discussions and suggestions. Our thanks to Jennifer Goodman, Albert Jimenez, Jennie Murphy, Natalie Morgan, Morgen Peck, Jennifer Galarza, Sidra Khalid Melinda Ruiz and Meredith Taylor for help with the breeding, behavioral experiments and operations. Dr. X. William Yang was supported by an NINDS/NIH (R01 NS049501) grant and grants from CHDI and HDF.
PY - 2009/9
Y1 - 2009/9
N2 - Huntington's disease (HD) is one of the few neurodegenerative diseases with a known genetic cause, knowledge that has enabled the creation of animal models using genetic manipulations that aim to recapitulate HD pathology. The study of behavioral and neuropathological phenotypes of these HD models, however, has been plagued by inconsistent results across laboratories stemming from the lack of standardized husbandry and testing conditions, in addition to the intrinsic differences between the models. We have compared different HD models using standardized conditions to identify the most robust phenotypic differences, best suited for preclinical therapeutic efficacy studies. With a battery of tests of sensory-motor function, such as the open field and prepulse inhibition tests, we replicate previous results showing a strong and progressive behavioral deficit in the R6/2 line with an average of 129 CAG repeats in a mixed CBA/J and C57BL/6J background. We present the first behavioral characterization of a new model, an R6/2 line with an average of 248 CAG repeats in a pure C57BL/6J background, which also showed a progressive and robust phenotype. The BACHD in a FVB/N background showed robust and progressive behavioral phenotype, while the YAC128 full-length model on either an FVB/N or a C57BL/6J background generally showed milder deficits. Finally, the HdhQ111 knock-in mouse on a CD1 background showed very mild deficits. This first extensive standardized cross-characterization of several HD animal models under standardized conditions highlights several behavioral outcomes, such as hypoactivity, amenable to standardized preclinical therapeutic drug screening.
AB - Huntington's disease (HD) is one of the few neurodegenerative diseases with a known genetic cause, knowledge that has enabled the creation of animal models using genetic manipulations that aim to recapitulate HD pathology. The study of behavioral and neuropathological phenotypes of these HD models, however, has been plagued by inconsistent results across laboratories stemming from the lack of standardized husbandry and testing conditions, in addition to the intrinsic differences between the models. We have compared different HD models using standardized conditions to identify the most robust phenotypic differences, best suited for preclinical therapeutic efficacy studies. With a battery of tests of sensory-motor function, such as the open field and prepulse inhibition tests, we replicate previous results showing a strong and progressive behavioral deficit in the R6/2 line with an average of 129 CAG repeats in a mixed CBA/J and C57BL/6J background. We present the first behavioral characterization of a new model, an R6/2 line with an average of 248 CAG repeats in a pure C57BL/6J background, which also showed a progressive and robust phenotype. The BACHD in a FVB/N background showed robust and progressive behavioral phenotype, while the YAC128 full-length model on either an FVB/N or a C57BL/6J background generally showed milder deficits. Finally, the HdhQ111 knock-in mouse on a CD1 background showed very mild deficits. This first extensive standardized cross-characterization of several HD animal models under standardized conditions highlights several behavioral outcomes, such as hypoactivity, amenable to standardized preclinical therapeutic drug screening.
UR - http://www.scopus.com/inward/record.url?scp=68249155312&partnerID=8YFLogxK
U2 - 10.1016/j.nbd.2009.05.007
DO - 10.1016/j.nbd.2009.05.007
M3 - Article
C2 - 19464370
AN - SCOPUS:68249155312
SN - 0969-9961
VL - 35
SP - 319
EP - 336
JO - Neurobiology of Disease
JF - Neurobiology of Disease
IS - 3
ER -